Evidence map›Paper›PMID 35734770›Full record

ArticleERJ open research2022

People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study.

Nigel S Cook, Gerard J Criner, Pierre-Régis Burgel, Katie Mycock, Tom Gardner, Phil Mellor, Pam Hallworth, Kate Sully, Sophi Tatlock, Beyza Klein and 7 more

Open access · goldAbstract read
In one paragraph

Article in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 6 countries.

Nigel S CookNovartis Pharma AG, Basel, Switzerland.ORCID https://orcid.org/0000-0001-8211-7613
Gerard J CrinerTemple University, Philadelphia, PA, USA.
Pierre-Régis BurgelCochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.ORCID https://orcid.org/0000-0003-0903-9828
Katie MycockAdelphi Real World, Macclesfield, UK.
Tom GardnerAdelphi Research, Macclesfield, UK.
Phil MellorAdelphi Research, Macclesfield, UK.
Pam HallworthAdelphi Research, Macclesfield, UK.
Kate SullyAdelphi Values, Macclesfield, UK.
Sophi TatlockAdelphi Values, Macclesfield, UK.
Beyza KleinNovartis Pharma AG, Basel, Switzerland.
Byron JonesNovartis Pharma AG, Basel, Switzerland.
Olivier Le RouzicLa Fondation du Souffle, Paris, France.
Kip AdamsCOPD Foundation, Miami, FL, USA.
Kirsten PhillipsLung Foundation Australia, Brisbane, Australia.
Mike McKevittBritish Lung Foundation, London, UK.
Kazuko ToyamaJ-Breath, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7280-6228
Florian S GutzwillerNovartis Pharma AG, Basel, Switzerland.ORCID https://orcid.org/0000-0001-7754-5744
Adelphi Group (United Kingdom) · GBNovartis (Switzerland) · CHInserm · FRBritish Lung Foundation · GBCOPD Foundation · USJapan Tobacco (Japan) · JPLung Foundation Australia · AUTemple University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This patient preference study sought to quantify the preferences of people living with COPD regarding symptom improvement in the UK, USA, France, Australia and Japan. Methods: The inclusion criteria were people living with COPD aged 40 years or older who experienced ≥1 exacerbation in the previous year with daily symptoms of cough and excess mucus production. The study design included: 1) development of an attributes and levels grid through qualitative patient interviews; and 2) implementation of the main online quantitative survey, which included a discrete choice experiment (DCE) to allow assessment of attributes and levels using hypothetical health state profiles. Preference weights (utilities) were derived from the DCE using hierarchical Bayesian analysis. A preference simulator was developed that enabled different health state scenarios to be evaluated based on the predicted patient preferences. Results: 1050 people living with moderate-to-severe COPD completed the survey. All attributes were considered important when patients determined their preferences in the DCE. In a health state preference simulation, two hypothetical health states (comprising attribute levels) with qualitatively equivalent improvements in A) cough and mucus and B) shortness of breath (SOB) resulted in a clear preference for cough and mucus improved profile. When comparing two profiles with C) daily symptoms improved and D) exacerbations improved, there was a clear preference for the daily symptoms improved profile. Conclusions: People living with moderate-to-severe COPD prefer to reduce cough and mucus production together over improvement of SOB and would prefer to reduce combined daily symptoms over an improvement in exacerbations.

Identifiers

PMID35734770
PMCPMC9205330
OpenAlexW4229063505

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.